Last update Jan. 4, 2024

Lisuride Maleate, Lysuride

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

It is a ergot derivative, dopamine D2-agonist, with actions and uses similar to those of bromocriptine. It is used in the treatment of Parkinson's disease and hyperprolactinemia. It has been used for suppression of physiological lactation (Sénat 2016). Oral administration.

Since the last update we have not found published data on its excretion in breastmilk.

Lisuride lowers prolactin levels and suppresses lactation. (Sénat 2016, Van Dam 1981)

The risk on breastfeeding would be due to its ability for suppression of milk production, but not to a possible effect on the infant which is considered very unlikely. 

If Lisuride was eventually administered to suppress lactation but afterwards the mother is willing to resuming breastfeeding, the mother can do it immediately, trying to minimize the drug effect by frequent suckling the child to stimulate milk production.

There is no evidence that pharmacological treatments are more effective than no treatment in suppressing lactation in the first week postpartum. Expert authors and professional consensus contraindicate pharmacological treatment to suppress lactation. (Marcellin 2015, Sénat 2015, Prescrire 2013, Oladapo 2012)


See below the information of this related product:

  • Hypergalactia; Hyperlactation (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

  • Cabergoline (Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Lisuride Maleate, Lysuride is also known as


Lisuride Maleate, Lysuride in other languages or writings:

Group

Lisuride Maleate, Lysuride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Lisuride Maleate, Lysuride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 10 - 22 %
Molecular weight 455 daltons
Protein Binding 66 %
pKa 15.36 -
Tmax 1 hours
2.2 - 10 hours

References

  1. Sénat MV, Sentilhes L, Battut A, Benhamou D, Bydlowski S, Chantry A, Deffieux X, Diers F, Doret M, Ducroux-Schouwey C, Fuchs F, Gascoin G, Lebot C, Marcellin L, Plu-Bureau G, Raccah-Tebeka B, Simon E, Bréart G, Marpeau L. Postpartum practice: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol. 2016 Abstract
  2. Marcellin L, Chantry AA. [Breast-feeding (part II): Lactation inhibition--Guidelines for clinical practice]. J Gynecol Obstet Biol Reprod (Paris). 2015 Abstract
  3. Sénat MV, Sentilhes L, Battut A, Benhamou D, Bydlowski S, Chantry A, Deffieux X, Diers F, Doret M, Ducroux-Schouwey C, Fuchs F, Gascoin G, Lebot C, Marcellin L, Plu-Bureau G, Raccah-Tebeka B, Simon E, Bréart G, Marpeau L. [Post-partum: Guidelines for clinical practice--Short text]. J Gynecol Obstet Biol Reprod (Paris). 2015 Dec;44(10):1157-66. Abstract
  4. [No authors listed] Do not use drugs to prevent onset of lactation. Relieve the discomfort and wait. Prescrire Int. 2013 Abstract
  5. Oladapo OT, Fawole B. Treatments for suppression of lactation. Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD005937. doi: 10.1002/14651858.CD005937.pub3. Full text (link to original source)
  6. Van Dam LJ, Rolland R. Lactation-inhibiting and prolactin-lowering effect of lisuride and bromocriptine: a comparative study. Eur J Obstet Gynecol Reprod Biol. 1981 Nov;12(5):323-30. Abstract

Total visits

5,554

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM